Suzanne Sorof, MD
Cardiovascular Disease · Phoenix, AZNPI 1942393004
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,390 of the $28,659 with a category attached, or 67.7%. 37 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 49.4% of the total. Reporting peaked in 2022 at $6,082 and has fallen 55.3% since, to $2,717 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $110.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$14K
- Kestra Medical Technology Services, Inc.$7K
- Bayer$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Amgen$486
- Johnson & Johnson$454
- plus $4K from 31 others
Across 1 payment — averaging $10,408 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$10K
What the payments were for
- Consulting fees$3,51112%
- Speaking & faculty fees$19,39068%
- Food & beverage$5,73720%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 26 | $14,146 |
| Kestra Medical Technology Services, Inc. | 17 | $6,548 |
| Bayer | 5 | $2,018 |
| Regeneron Healthcare Solutions, Inc. | 6 | $1,299 |
| Amgen | 17 | $486 |
| Johnson & Johnson | 24 | $454 |
| Novartis | 29 | $373 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $340 |
| Abbott | 9 | $327 |
| Philips North America LLC | 2 | $266 |
| Boehringer Ingelheim | 11 | $247 |
| E.r. Squibb & Sons, L.L.C. | 15 | $211 |
| Pfizer | 13 | $208 |
| EKOS Corporation | 3 | $159 |
| Abiomed | 3 | $152 |
| Novo Nordisk | 2 | $142 |
| AstraZeneca | 8 | $133 |
| Impulse Dynamics (USA) Inc. | 2 | $123 |
| Alnylam Pharmaceuticals Inc. | 7 | $121 |
| Boston Scientific | 6 | $103 |
| Inspire Medical Systems, Inc. | 1 | $97 |
| Sanofi-aventis U.S. LLC | 5 | $95 |
| Medtronic | 2 | $88 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $77 |
| ZOLL Respicardia, Inc. | 4 | $68 |
| Merck | 3 | $50 |
| Astellas Pharma US Inc | 2 | $44 |
| Gilead | 3 | $39 |
| Irhythm Technologies, Inc. | 2 | $39 |
| Teleflex LLC | 1 | $33 |
| Lundbeck LLC | 2 | $33 |
| Itamar Medical Inc | 2 | $33 |
| Bardy Diagnostics, Inc. | 2 | $30 |
| Cvrx, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$13,650
- OPSUMIT$10,725
- Assure WCD$6,231
- Adempas$1,960
- PRALUENT$1,250
- Spectranetics Undiv$250
- OPTIMIZER$229
- Repatha$212
- CARDIOMEMS$168
- EKOSONIC$125
- XARELTO$121
- Impella$120
- Ozempic$119
How this compares
$28,659 in reported general payments places this provider in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 11 | $155,213 |
| EliquisApixaban | 84 | $94,985 |
| JardianceEmpagliflozin | 34 | $51,049 |
| XareltoRivaroxaban | 11 | $14,518 |
| FarxigaDapagliflozin Propanediol | 12 | $12,473 |
| Rosuvastatin Calcium | 220 | $3,181 |
| Nifedipine ErNifedipine | 71 | $2,012 |
| Atorvastatin Calcium | 146 | $1,503 |
| Metoprolol Succinate | 89 | $1,274 |
| Losartan Potassium | 104 | $1,200 |
| Lisinopril | 173 | $1,123 |
| Carvedilol | 118 | $947 |
| Ezetimibe | 20 | $909 |
| Hydralazine Hcl | 42 | $830 |
| ClopidogrelClopidogrel Bisulfate | 51 | $811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $2,018 | $155,21311 claims |
| PfizerEliquis | $208 | $94,98584 claims |
| Boehringer IngelheimJardiance | $247 | $51,04934 claims |
| Johnson & JohnsonXarelto | $454 | $14,51811 claims |
| AstraZenecaFarxiga | $133 | $12,47312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Phoenix
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Tabitha MoePhoenix$182K
- Jesse SethiPhoenix$150K
- Robert ScottPhoenix$106K
- Kethes WaramPhoenix$66K
- Ayman JamalPhoenix$42K
- Sarika DesaiPhoenix$41K
- Namit RohantPhoenix$25K
- Venkataramanan GangadharanPhoenix$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.